---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-075849"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2026-06-18T21:14:49+00:00"
generated_at: "2026-06-18T21:17:01.035658+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Petros Pharmaceuticals CFO Arnold departs; Robert Weinstein appointed as CAO/PFO

## Summary
- Mitchell Arnold mutually separated as VP Finance, Principal Financial & Accounting Officer, effective June 18, 2026.
- Robert Weinstein appointed as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately.
- Separation includes $38,500 severance (2 months salary), accelerated vesting of 3,000 unvested shares, and 2 months COBRA premium subsidy.
- Weinstein brings 30+ years experience; most recently CFO of TAO Synergies (formerly Synaptogenix) since 2013.

## SEC filing metadata
- accession: 0001104659-26-075849
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2026-06-18T21:14:49+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/0001104659-26-075849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/tm2618334d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-075849
- JSON: https://secwatch.observer/filing/0001104659-26-075849.json
- Plain text: https://secwatch.observer/filing/0001104659-26-075849.txt

## Key facts
- Executive change
  Robert Weinstein was appointed as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer at Petros Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
  source text: On June 18, 2026, the board of directors (the “Board”) of the Company appointed Robert Weinstein to the positions of Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/0001104659-26-075849-index.htm
- Executive change
  Mitchell Arnold departed as Vice President of Finance, Principal Accounting Officer and Principal Financial Officer at Petros Pharmaceuticals, Inc..
  - Action: separated
  - Role: Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
  source text: On June 18, 2026, Petros Pharmaceuticals, Inc. (the “Company”) and Mitchell Arnold, who served as the Company’s Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, mutually agreed to the separation of Mr. Arnold from such roles, effective as of June 18, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/0001104659-26-075849-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.